Clinical investigation of medicinal products for the treatment of ankylosing spondylitis

  • Email
  • Help
Current effective version

Adopted guideline

Currently under revision - see below

Reference numberCPMP/EWP/4891/03
Published23/04/2009
Effective from01/11/2009
KeywordsAnkylosing spondylitis, axial spondyloarthritis, spondyloarthritis, chronic inflammatory diseases
DescriptionThis document provides guidance for the clinical evaluation of new medicinal products for the treatment of ankylosing spondylitis. It addresses the patient characteristics and selection criteria, as well as efficacy assessement. It outlines strategies for early studies in man (dose-response trials) as well as for therapeutic confirmatory trials and specific aspects of evaluation of clinical safety.


Document history

Revision 1

In progress

Adopted guideline



Draft guideline 
 

Concept paper

Published: 31/10/2017
Effective from: 01/05/2018
 

Published: 01/07/2016
 

Published: 01/04/2015

First version

Current version

Adopted guideline


Overview of comments


Draft guideline

In operation: 01/11/2009–present


Published: 23/04/2009


Published: 23/06/2005


Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more